REGISTER
Haisco Files Another Indication for HSK39297
Haisco’s selective factor B inhibitor HSK39297 has had a new marketing application accepted in China, likely for paroxysmal nocturnal hemoglobinuria patients who remain anemic despite stable prior C5 monoclonal antibody therapy, further advancing domestic development in the CFB inhibitor space.

On March 6, the website of the Center for Drug Evaluation showed that the new indication marketing application for Haisco’s Class 1 innovative drug HSK39297 tablets had been accepted. Based on the progress of the program, the Insight database inferred that the submitted indication may be for the treatment of patients with paroxysmal nocturnal hemoglobinuria who remain anemic despite stable prior use of a C5 monoclonal antibody.

HSK39297 is an efficient and selective small-molecule factor B inhibitor independently developed by Haisco. By inhibiting factor B activity, it blocks activation of the alternative pathway and the complement amplification loop, thereby inhibiting the activity of the entire complement pathway. It is intended for the treatment of various diseases mediated by abnormal complement activation.

In patients with paroxysmal nocturnal hemoglobinuria, intravascular hemolysis is mediated by the membrane attack complex at the terminal complement pathway, whereas extravascular hemolysis is mediated by C3b opsonization. HSK39297 acts proximally in the alternative pathway of the complement cascade, controlling both C3b-mediated extravascular hemolysis and terminal complement-mediated intravascular hemolysis.

In January 2026, the first marketing application for HSK39297 was accepted by the CDE for adult patients with paroxysmal nocturnal hemoglobinuria who had not previously received complement inhibitor therapy, and that application was included in the priority review pathway.

In addition, Haisco has conducted a multicenter, single-arm, open-label Phase III clinical study, registration number CTR20251209, to evaluate the efficacy and safety of HSK39297 tablets in patients with paroxysmal nocturnal hemoglobinuria who remain anemic despite stable prior C5 monoclonal antibody treatment. The study was completed in January this year.

In addition to the above indications, Haisco is also exploring the potential of HSK39297 in other diseases in clinical studies, including IgA nephropathy and lupus nephritis.

Summary

According to the Insight database, in the CFB inhibitor space, the only approved product both globally and in China is Novartis’s iptacopan. Iptacopan was first approved at the end of 2023, achieved sales of USD 129 million in 2024, and grew 291% year over year to USD 505 million in 2025.

In China, besides iptacopan, there are currently three CFB inhibitors under marketing review, all domestic products, from Longbio Technology with MY008211A, Haisco with HSK39297, and Hengrui Medicine with lerkocopan. The first indication for all three is paroxysmal nocturnal hemoglobinuria, and all have been included in priority review.

0
0
Loading